Next Article in Journal
Investigating Hydrogen Isotope Variation during Heating of n-Alkanes under Limited Oxygen Conditions: Implications for Palaeoclimate Reconstruction in Archaeological Settings
Next Article in Special Issue
Approaches for Mitigating Microbial Biofilm-Related Drug Resistance: A Focus on Micro- and Nanotechnologies
Previous Article in Journal
Polymerized Whey Protein Concentrate-Based Glutathione Delivery System: Physicochemical Characterization, Bioavailability and Sub-Chronic Toxicity Evaluation
Previous Article in Special Issue
Phytochemical Profiling, In Vitro and In Silico Anti-Microbial and Anti-Cancer Activity Evaluations and Staph GyraseB and h-TOP-IIβ Receptor-Docking Studies of Major Constituents of Zygophyllum coccineum L. Aqueous-Ethanolic Extract and Its Subsequent Fractions: An Approach to Validate Traditional Phytomedicinal Knowledge
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 26
Issue 7
10.3390/molecules26071829
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis and Evaluation of Thymol-Based Synthetic Derivatives as Dual-Action Inhibitors against Different Strains of H. pylori and AGS Cell Line

by
Francesca Sisto
1,
Simone Carradori
2,*,
Paolo Guglielmi
3,
Mattia Spano
3,
Daniela Secci
3,
Arianna Granese
3,
Anatoly P. Sobolev
4,
Rossella Grande
2,
Cristina Campestre
2,
Maria Carmela Di Marcantonio
5 and
Gabriella Mincione
5
1
Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy
2
Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy
3
Department of Chemistry and Technology of Drugs, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy
4
Institute for Biological Systems, “Annalaura Segre” Magnetic Resonance Laboratory, CNR, 00015 Rome, Italy
5
Department of Innovative Technologies in Medicine and Dentistry, “G. d’Annunzio” University of Chieti-Pescara, 66100 Chieti, Italy
*
Author to whom correspondence should be addressed.
Molecules 2021, 26(7), 1829; https://doi.org/10.3390/molecules26071829
Submission received: 7 March 2021 / Revised: 22 March 2021 / Accepted: 23 March 2021 / Published: 24 March 2021
(This article belongs to the Special Issue Novel Biologically Active Molecules, Biomaterials and Nanoparticles for the Microbial Biofilm Control in Human Medicine)
Browse Figure
Versions Notes

Abstract

:
Following a similar approach on carvacrol-based derivatives, we investigated the synthesis and the microbiological screening against eight strains of H. pylori, and the cytotoxic activity against human gastric adenocarcinoma (AGS) cells of a new series of ether compounds based on the structure of thymol. Structural analysis comprehended elemental analysis and 1H/13C/19F NMR spectra. The analysis of structure–activity relationships within this molecular library of 38 structurally-related compounds reported that some chemical modifications of the OH group of thymol led to broad-spectrum growth inhibition on all isolates. Preferred substitutions were benzyl groups compared to alkyl chains, and the specific presence of functional groups at para position of the benzyl moiety such as 4-CN and 4-Ph endowed the most anti-H. pylori activity toward all the strains with minimum inhibitory concentration (MIC) values up to 4 µg/mL. Poly-substitution on the benzyl ring was not essential. Moreover, several compounds characterized by the lowest minimum inhibitory concentration/minimum bactericidal concentration (MIC/MBC) values against H. pylori were also tested in order to verify a cytotoxic effect against AGS cells with respect to 5-fluorouracil and carvacrol. Three derivatives can be considered as new lead compounds alternative to current therapy to manage H. pylori infection, preventing the occurrence of severe gastric diseases. The present work confirms the possibility to use natural compounds as templates for the medicinal semi-synthesis.

1. Introduction

Thymol, a major natural monoterpene phenol in the essential oils of Lamiaceae and Apiaceae families, has been approved by European Union and Food and Drug Administration as a safe food additive as well as in cosmetics and agriculture industry. Among the terpenes, it has been demonstrated to be clinically relevant as an antimicrobial, antioxidant, and anti-inflammatory agent [1]. As well as its regioisomer carvacrol, thymol could exert an inhibitory effect on Gram-positive and Gram-negative bacteria, but only few studies were oriented toward H. pylori [2,3], preferring the use of standardized thymol-containing plant extracts for the eradication. This Gram-negative and microaerophilic pathogen colonizes and survives in the human gastric epithelium, which represents its favourite ecological niche. About 50% of the global population is colonized by the microorganism although in most cases H. pylori causes no symptoms [4]. The survival of the microorganism as well as the recalcitrance of the infection are due to H. pylori aptitude to adapt itself to the host and to develop resistance towards the antimicrobials commonly used in therapy [5]. The resistance rate to the clinically approved drugs is increasing worldwide and most of the therapeutic failures are ascribed to adaptive mechanisms linked to the biofilm formation [6], which limit the efficacy of the current therapy. The triple therapy based on the administration on proto-pump inhibitor and two antibiotics has been considered the standard therapy for many years, however, the increasing rate of triple-therapy failure was registered in many countries as well as the spreading of H. pylori antibiotic resistance. In this context, novel compounds such as components of essential oils endowed with alternative mechanisms of action and the ability to disaggregate lipidic multilayer structures are strongly suggested [7]. More in detail, thymol derivatives have been proposed as inhibitors of CagA and VacA (cytotoxin-associated gene A and vacuolization cytotoxin) oncoproteins of Helicobacter pylori [8] and, recently, Bkhaitan et al. also prepared a thymol-metronidazole ester hybrid and assessed its discrete anti-Helicobacter pylori activity and limited cytotoxicity on normal cell lines [9].
In addition, H. pylori is considered as a class I carcinogen by the World Health Organization and can secrete virulence factors, which not only affect host signalling pathways but can also induce a sustained gastric inflammatory process ultimately leading to the development of cancerous conditions in the stomach and duodenum [10]. In the last years, thymol has been the focus of some research studies on the potential suppression of cancer cell growth [11], ascribing to this molecule the capability to induce apoptosis; cause morphological changes; generate reactive oxygen species; depolarize the potential of mitochondrial membrane; and activate Bax, caspases and PARP (Poly (ADP-ribose) polymerase). It was also tested against the human gastric carcinoma cells (AGS) with contrasting biological results. Indeed, Kang et al. reported an IC50 of 400 µM after 24 h of treatment [12], whereas Günes-Bayir et al. disclosed an IC50 of 75.63 µM [13]. Despite the reported values, it was evident that the cytotoxic effects on AGS cells were mediated in a concentration-dependent manner by the activation of apoptotic pathways prolonging the sub-G1 phase, generation of reactive oxygen species (ROS) especially at higher doses, and glutathione (GSH) depletion [14].
Starting from these important premises, we aimed at modifying the structure of this well-known natural product in order to achieve a small library of novel dual-action ether compounds, which can address multifaceted pathological conditions such as H. pylori-induced gastric cancer and provide a better resistance to the acidic gastric environment.

2. Results and Discussion

2.1. Chemistry

For the synthesis of compounds 2–39, we employed the synthetic approach reported in Figure 1. Compounds 2–7 and 9–39 (Figure 1a) have been synthesized taking advantage of the Williamson etherification procedure previously employed by our group for the synthesis of carvacrol derivatives [15]. Thymol (1) was reacted with the proper bromide in dry N,N’-dimethylformamide (DMF), in the presence of anhydrous potassium carbonate (K2CO3) and under nitrogen (N2) atmosphere. These reactions were performed at room temperature (RT) in order to avoid the reagent degradation. For the synthesis of compound 8 (Figure 1b) we started from compound 13 that underwent the hydrolysis of the ethyl ester group to afford the carboxylic acid moiety. The hydrolysis was performed in mild conditions using lithium hydroxide (LiOH) monohydrate, in a mixture of water and methanol (in the ratio 50:50, v:v) at room temperature.
The choice of such substituent was driven by the observation of a greater inhibition of microbial growth after the introduction of bulkier alkyl/benzyl groups on the hydroxyl moiety. The obtained compounds were stable at room temperature. The structures were confirmed by spectral studies (1H, 13C, and 19F NMR), whereas the purity of these compounds was confirmed by combustion analysis, Thin Layer Chromatography (TLC) parameters and, for solid compounds, melting point.

2.2. Anti-Helicobacter pylori Activity and Structure-Activity Relationship Studies

After the procedures of purification and characterization and the in silico analysis of drug-likeness, all the compounds (1–39) were tested in vitro against H. pylori growth and the 12 most promising ones also against AGS cells to suggest dual-action agents useful for the treatment of H. pylori-related gastric cancer development.
The phenolic terpene thymol and its 38 semi-synthetic derivatives were firstly assayed against eight strains of H. pylori (one reference and seven clinical isolates). All the strains were classified according to their antimicrobial susceptibility to metronidazole, clarithromycin, and amoxicillin following the international EUCAST (European Committee on Antimicrobial Susceptibility Testing) breakpoints. Thymol, with respect to carvacrol, displayed a weaker inhibitory activity against all the strains used with MIC and MBC values ranging from 64–128 µg/mL. These results are in accordance with those reported in the literature [16,17,18].
Four clinical isolates, namely F1, F40/499, F4, and F34/497, were the most sensitive to the treatment with thymol (1) (MIC/MBC of 64 µg/mL), slightly better than the values reported for other clinical isolates [19]. Similar results were obtained for carvacrol. The derivatives, functionalized at the OH moiety of the parent compound, can be clustered into two groups (alkyloxy and benzyloxy/heteroarylmethyloxy compounds) in order to extrapolate robust structure–activity relationship (SAR) within this scaffold (Table 1). The most important information is that the OH group, as in carvacrol-based derivatives, did not seem to be essential at least to display anti-H. pylori activity. Other ether groups can be tolerated suggesting a specific mechanism of action with respect to the direct alteration of the bacterial membrane.
Among the first cluster of alkyloxy derivatives (2–14), the MIC results demonstrated no or weak efficacy against all the strains as well as their parent compound, despite the presence of branched alkyl chains, unsaturations or specific functional groups (ketone, carboxylic acid, ethyl ester). Only three derivatives (3, 9, 12) with linear and increasing alkyl chains (Et, n-Pr, n-Bu) presented improved MIC values with respect to thymol against some clinical isolates (MIC/MBC = 16 µg/mL). Similar results were obtained for the aliphatic derivatives of carvacrol in our previous paper [15].
Among the second cluster of benzyloxy and heteroarylmethyloxy derivatives (15–39), the simplest and unsubstituted compound (15) was slightly more potent than thymol, but the introduction of electron-withdrawing or electron-donating substituents at different positions induced an opposite trend on the inhibitory activity. Substitutions at the ortho position of the benzyl group were usually detrimental (compounds 16, 20, 31) except for the potent activity of compound 34 (o-NO2) on specific strains (MIC range 4–8 µg/mL, MBC range 8–16 µg/mL). Methoxy (19), chloro (28), and nitro (35) at meta position did not alter the anti-Helicobacter pylori activity, whereas m-CF3 (21) dramatically reduced it and m-F (25) elicited it. As reported for carvacrol-based compounds, derivatives with para substitution were generally more potent (17, 29, 32), except for 33 and 36. Two derivatives (24 and 38), with 4-CN and 4-Ph respectively, were endowed with the most anti-H. pylori activity toward all the considered strains with MIC values up to 4 µg/mL. Poly-substitution on the benzyl ring was not important (18 and 23), albeit three compounds (26, 27, 30) slightly improved the antimicrobial activity with respect to thymol. Finally, the insertion on the OH group of thymol of a naphthalene ring (37) was detrimental, whereas the presence of a phthalimide nucleus (39) enhanced the activity. Collectively, these data suggested for all the derivatives a bactericidal mechanism of action, considering the MBC/MIC ratio to be between 1–2. This biological activity did not seem to be strictly correlated to the presence of a slightly acidic and polar phenolic OH.

2.3. Effects of Thymol and Its Semi-Synthetic Derivatives on AGS Cell Viability

To better assess the dual-action behaviour of these compounds, the selection of the candidates for biological assays was guided by the anti-Helicobacter pylori activity (Table 1, compounds highlighted in grey). AGS cells were incubated for 24 h with the specified molecules or with 0.1% dimethyl sulfoxide (DMSO) vehicle (control). Data shown are the means ± SD of three experiments with quintuplicate determinations (Table 2). Thymol (1) showed discrete cytotoxic effects by reducing cell viability of AGS cells (IC50 = 200 ± 6.5 μM) in a dose-dependent manner, which is in accordance with literature data [12]. It displayed a stronger cytotoxic effect at 24 h with respect to its positional isomer carvacrol (IC50 = 300 ± 6.4 μM). Out of 11 thymol derivatives, only three (9, 15, 38) presented a dose-dependent inhibitory effect on cell viability inferior to thymol. All of them possessed an IC50 value higher than the reference drug 5-fluorouracil (5-FU, IC50 = 82.3 ± 5.6 μM).
Collectively, the functionalization of the OH moiety with an unsubstituted benzyloxy group (15) or a linear alkyloxy chain (9) was preferred in eliciting the inhibitory activity below 100 μM. The substitution of the benzyl ring with NO2, F, and CN led to a reduction of the biological effect as well as the poly-substitution (26 and 30). The change of the benzyl group with a phthalimide (39) was detrimental. Interestingly, compound 38 with a 4-Ph on the benzyl ring exerted a comparable activity with respect to the parent compound.

2.4. Pan Assay Interference Compounds (PAINS) and Drug-Likeness Evaluation

In addition, we selected three representative and dual-action compounds (9, 15, and 38) for a broader analysis (SwissADME) of their chemical-physical characteristics and Medicinal Chemistry properties (Table 3) [20,21].
All designed inhibitors have been analyzed by means of theoretical tools regarding the possibility to act as interfering/covalent compounds in different in vitro assays. Indeed, the analysis of substructures to elicit promiscuous pharmacological behaviour, commonly named PAINS, should be mandatory in Medicinal Chemistry for a further and proper development of such compounds in the clinical settings. Our top-rated thymol derivatives were devoid of this property. Moreover, their drug-likeness was evaluated based on the Lipinski’s rule of five, largely met by all the derivatives (for compounds 15 and 38, MLOGP > 4.15, which approximatively corresponds to CLogP ˃ 5, was the only violation). Log P, calculated by Moriguchi-based computer program (MLOGP), is one of the parameters that can estimate the proper absorption or permeation of a drug candidate [22]. In fact, compound 38 has also a low gastro-intestinal absorption owing to its very high MLOGP value. These features, if focused on drugs acting after oral administration specifically on the H. pylori-colonized gastric mucosa, should not be considered negatively. Interestingly, as proposed by the SwissADME tool, these compounds do not display any kind of interaction with permeability glycoprotein (P-gp) that promotes the efflux of cytotoxic drugs out of the cells. This characteristic is suitable to enhance the efficacy of anti-proliferative agents, due to the involvement of this protein in the multi-drug resistance [23]. The other parameters, as reported in the footnote of Table 3, were used for the construction of both the boiled-egg graph and the bioavailability radar. The former allows an easy understanding and visualization of the passive absorption at the GI tract (white area) and the ability to permeate the blood brain barrier (BBB, yellow area). Only compounds 9 and 15 are able to be easily absorbed by the GI and provide the possibility to cross the BBB. Finally, the information obtained from the bioavailability radar graphical output suggests the drug-likeness depiction of the selected compounds including the optimal range of each physical-chemical property (flexibility, size, lipophilicity, polarity, saturation, solubility) essential to provide oral bioavailability. Collectively, these computed data are of interest for the clinical development of compounds acting as antibacterial or anti-cancer.

3. Materials and Methods

3.1. Chemistry

All reactions were carried out under a positive pressure of nitrogen in washed and oven-dried glassware. All the solvents and high-purity reagents were directly used as supplied by Sigma-Aldrich (Milan, Italy) without further purification. Where mixtures of solvents are specified, the stated ratios are volume:volume. All melting points were measured on a Stuart® melting point apparatus SMP1 and are uncorrected (temperatures are reported in °C). Structural analysis consisted of elemental analysis and 1H/13C/19F NMR spectra. 1H and 13C-NMR spectra were recorded both at 300 MHz and 75 MHz (Varian Mercury spectrometer, Varian, Santa Clara, CA, USA), while other compounds were analysed at 400 MHz and 101 MHz on a Bruker spectrometer (Milan, Italy), using CDCl3 and DMSO-d6, as the solvents at room temperature. Conversely, 19F spectra were recorded on a Bruker AVANCE 600 spectrometer at 564.7 MHz, using CDCl3 as the solvent. All the compounds were studied at the final concentration of ~25 mg/mL. 1H and 13C chemical shifts are expressed as δ units (parts per millions) and referenced to the residual solvent signal (CDCl3 δH 7.26 ppm and δC 77.2 ppm, DMSO-d6 δH 3.33 and δC 39.5 ppm), whereas 19F chemical shifts are expressed as δ units relative to an external standard (CF3COOH, δ−76.55 ppm). 1H spectra are described as follows: δH (spectrometer frequency, solvent): chemical shift/ppm (multiplicity, J-coupling constant(s) in Hertz (Hz), number of protons, assignment). 13C spectra are described as follows: δC (spectrometer frequency, solvent): chemical shift/ppm (assignment) and are fully proton decoupled. 19F spectra are described as follows: δF (spectrometer frequency, solvent): chemical shift/ppm (multiplicity, J coupling constant(s) in Hertz, number of fluorine, assignment) and are reported as Supplementary Materials. Multiplets are abbreviated as follows: br—broad; s—singlet; d—doublet; t—triplet; —quartet; td—triplet of doublets; m—multiplet. The exchangeable protons (OH) were assessed by the addition of deuterium oxide. The processing and analyses of the NMR data were carried out with MestreNova. Elemental analyses for C, H, and N were recorded on a Perkin-Elmer 240 B microanalyzer obtaining analytical results within ± 0.5% of the theoretical values for the final compounds. Preparative chromatography was carried out employing silica gel (high purity grade, pore size 60 Å, 230–400 mesh particle size). All the purifications and reactions were carried out by thin layer chromatography (TLC) performed on 0.2-mm-thick silica gel-aluminium backed plates (60 F254). Spot visualization was performed under short and long wavelengths (254 and 365 nm, respectively) ultra-violet irradiation. Where given, systematic compound names were generated by ChemBioDraw Ultra 14.0 following IUPAC conventions.

3.2. Synthesis of Thymol Derivatives

3.2.1. General Procedure for the Synthesis of Compounds 2–7 and 9–39

To a stirring solution of thymol (1, 1.0 equiv.) in dry DMF (10 mL) was added freshly ground and anhydrous potassium carbonate (K2CO3, 1.1 equiv.) under N2 atmosphere. The suspension was stirred for 15 min at room temperature; then, the proper (un)substituted benzyl or alkyl bromide (1.5 equiv.) was added and the reaction stirred until disappearance of the starting reagents, as detected by TLC (24–72 h). Once the reaction was completed, the mixture was poured into ice-cold water (100 mL) and extracted with dichloromethane (DCM, 3 × 20 mL). The organics were collected, dried over sodium sulphate (Na2SO4), and evaporated in vacuo to afford the crude mixture that was purified through silica gel column chromatography, using proper mixtures of n-hexane/ethyl acetate as mobile phase.

3.2.2. Synthesis of Compound 8

To a stirring solution of ethyl 2-(2-isopropyl-5-methylphenoxy)acetate (13, 1.0 equiv.) in 10 mL of methanol was added dropwise a solution of lithium hydroxide (1.2 equiv.) in 10 mL of water. The reaction was stirred at room temperature for 24 h; then, the mixture was concentrated in vacuo to remove methanol and quenched with 3N HCl (15 mL). The precipitate was collected by filtration and washed with n-hexane to give the title compound 8, without further purification requirements.

3.3. Characterization Data for Thymol Derivatives 2–39

2-ethoxy-1-isopropyl-4-methylbenzene (2): colourless oil, 75% yield. 1H-NMR (400 MHz, CDCl3): δ 1.26–1.28 (m, 6H, 2 × CH3), 1.46–1.50 (m, 3H, CH3), 2.38 (s, 3H, ArCH3), 3.31–3.41 (m, 1H, CH), 4.06–4.11 (m, 2H, OCH2), 6.72 (s, 1H, Ar), 6.79 (d, J = 8.0 Hz, 1H, Ar), 7.15 (d, J = 8.0 Hz, 1H, Ar). 13C-NMR (101 MHz, CDCl3): δ 15.0 (CH3), 15.9 (ArCH3), 24.1 (2 × CH3), 34.2 (CH), 63.5 (OCH2), 109.6 (Ar), 117.9 (Ar), 124.1 (Ar), 130.4 (Ar), 147.8 (Ar), 157.1 (Ar). Anal. Calcd for C12H18O: C, 80.85; H, 10.18. Found: C, 80.79; H, 10.13.
1-isopropyl-4-methyl-2-propoxybenzene (3): colourless oil, 72% yield. 1H-NMR (300 MHz, CDCl3): δ 1.38–1.43 (m, 3H, CH3), 1.58 (d, J = 7.2 Hz, 6H, 2 × CH3), 2.10–2.19 (m, 2H, CH2), 2.66 (s, 3H, ArCH3), 3.64–3.71 (m, 1H, CH), 4.21–4.25 (m, 2H, OCH2), 6.99 (s, 1H, Ar), 7.06 (d, J = 8.1 Hz, 1H, Ar), 7.43 (d, J = 7.5 Hz, 1H, Ar). 13C-NMR (75 MHz, CDCl3): δ 11.1 (CH3), 21.6 (ArCH3), 23.1 (CH2), 23.2 (2 × CH3), 27.0 (CH), 69.6 (OCH2), 112.3 (Ar), 121.2 (Ar), 126.1 (Ar), 134.3 (Ar), 136.4 (Ar), 156.5 (Ar). Anal. Calcd for C13H20O: C, 81.20; H, 10.48. Found: C, 81.20; H, 10.45.
2-(allyloxy)-1-isopropyl-4-methylbenzene (4): colourless oil, 64% yield. 1H-NMR (300 MHz, CDCl3): δ 1.54 (d, J = 6.6 Hz, 6H, 2 × CH3), 2.61 (s, 3H, ArCH3), 3.62–3.72 (m, 1H, CH), 4.77–4.80 (m, 2H, OCH2), 5.52–5.56 (m, 1H, =CH2), 5.70–5.77 (m, 1H, =CH2), 6.30–6.41 (m, 1H, =CH), 6.94 (s, 1H, Ar), 7.04 (d, J = 7.8 Hz, 1H, Ar), 7.40 (d, J = 8.1 Hz, 1H, Ar). 13C-NMR (75 MHz, CDCl3): δ 21.6 (ArCH3), 23.0 (2 × CH3), 26.9 (CH), 68.9 (OCH2), 112.8 (Ar), 116.8 (=CH2), 121.6 (Ar), 126.8 (Ar), 134.0 (=CH), 134.5 (Ar), 136.4 (Ar), 156.0 (Ar). Anal. Calcd for C13H18O: C, 82.06; H, 9.54. Found: C, 82.03; H, 9.55.
1-isopropyl-4-methyl-2-(prop-2-yn-1-yloxy)benzene (5): colourless oil, 82% yield. 1H-NMR (300 MHz, CDCl3): δ 1.57–1.60 (m, 6H, 2 × CH3), 2.67 (s, 3H, ArCH3), 2.74 (t, J = 2.4 Hz, 1H, ≡CH), 3.67–3.70 (m, 1H, CH), 4.93–4.95 (m, 2H, OCH2), 7.09 (s, 1H, Ar), 7.13 (d, J = 8.4 Hz, 1H, Ar), 7.44–7.48 (m, 1H, Ar). 13C-NMR (75 MHz, CDCl3): δ 21.6 (ArCH3), 23.2 (2 × CH3), 26.8 (CH), 56.2 (OCH2), 75.5 (≡CH), 79.5 (C≡), 113.3 (Ar), 122.6 (Ar), 126.4 (Ar), 134.9 (Ar), 136.4 (Ar), 155.1 (Ar). Anal. Calcd for C13H16O: C, 82.94; H, 8.57. Found: C, 82.97; H, 8.60.
2-(2-isopropyl-5-methylphenoxy)acetonitrile (6): white sticky solid, 72% yield. 1H-NMR (300 MHz, CDCl3): δ 1.23–1.25 (m, 6H, 2 × CH3), 2.38 (s, 3H, ArCH3), 3.28–3.30 (m, 1H, CH), 4.77–4.78 (s, 2H, OCH2), 6.75 (s, 1H, Ar), 6.91 (d, J = 7.8 Hz, 1H, Ar), 7.19 (d, J = 7.5 Hz, 1H, Ar). 13C-NMR (75 MHz, CDCl3): δ 21.3 (ArCH3), 22.9 (2 × CH3), 26.5 (CH), 53.9 (OCH2), 112.9 (Ar), 115.5 (CN), 123.8 (Ar), 126.7 (Ar), 135.0 (Ar), 136.8 (Ar), 153.8 (Ar). Anal. Calcd for C12H15NO: C, 76.16; H, 7.99; N, 7.40. Found: C, 76.20; H, 8.03; N, 7.37.
1-(2-isopropyl-5-methylphenoxy)propan-2-one (7): amber-yellow oil, 90% yield. 1H-NMR (300 MHz, CDCl3): δ 1.30 (d, J = 7.2 Hz, 6H, 2 × CH3), 2.35–2.36 (m, 6H, CH3 + ArCH3), 3.29–3.43 (m, 1H, CH), 4.54 (s, 2H, OCH2), 6.55 (s, 1H, Ar), 6.84 (d, J = 7.8 Hz, 1H, Ar), 7.18 (d, J = 7.5, 1H, Ar). 13C-NMR (75 MHz, CDCl3): δ 21.3 (ArCH3), 22.8 (2 × CH3), 26.7 (CH3), 26.8 (CH), 73.2 (OCH2), 112.0 (Ar), 122.3 (Ar), 126.3 (Ar), 134.1 (Ar), 136.5 (Ar), 154.8(Ar), 206.6 (C=O). Anal. Calcd for C13H18O2: C, 75.69; H, 8.80. Found: C, 75.72; H, 8.77.
2-(2-isopropyl-5-methylphenoxy)acetic acid(8): white solid, 87% yield, mp = 143–145 °C. 1H-NMR (300 MHz, CDCl3): δ 1.23 (d, J = 6.9 Hz, 6H, 2 × CH3), 2.32 (s, 3H, ArCH3), 3.32–3.37 (m, 1H, CH), 4.69 (s, 2H, OCH2), 6.57 (s, 1H, Ar), 6.82 (d, J = 7.5 Hz, 1H, Ar), 7.14 (d, J = 7.5 Hz, 1H, Ar), 8.40 (bs, 1H, COOH). 13C-NMR (75 MHz, CDCl3): δ 21.3 (ArCH3), 22.8 (2 × CH3), 26.6 (CH), 65.2 (OCH2), 112.4 (Ar), 122.7 (Ar), 126.4 (Ar), 134.5 (Ar), 136.5 (Ar), 154.5 (Ar), 174.9 (CO). Anal. Calcd for C12H16O3: C, 69.21; H, 7.74. Found: C, 69.27; H, 7.77.
2-butoxy-1-isopropyl-4-methylbenzene (9): colourless oil, 75% yield. 1H-NMR (300 MHz, CDCl3) δ 1.27–1.32 (m, 3H, CH3), 1.53 (d, J = 6.3 Hz, 6H, 2 × CH3), 1.77–1.90 (m, 2H, CH2), 2.04–2.13 (m, 2H, CH2), 2.62 (s, 3H, ArCH3), 3.59–3.68 (m, 1H, CH), 4.21–4.25 (m, 2H, O CH2), 6.96 (s, 1H, Ar), 7.02 (d, J = 7.5 Hz, 1H, Ar), 7.39 (d, J = 7.5 Hz, 1H, Ar). 13C-NMR (75 MHz, CDCl3): δ 14.1 (CH3), 19.8 (CH2), 21.6 (ArCH3), 23.0 (2 × CH3), 26.9 (CH), 31.9 (CH2), 67.6 (OCH2), 112.3 (Ar), 121.1 (Ar), 126.0 (Ar), 134.2 (Ar), 136.4 (Ar), 156.5 (Ar). Anal. Calcd for C14H22O: C, 81.50; H, 10.75. Found: C, 81.55; H, 10.83.
2-(but-2-en-1-yloxy)-1-isopropyl-4-methylbenzene (10): pale yellow oil, 81% yield. 1H-NMR (300 MHz, CDCl3): δ 1.47 (d, J = 7.2 Hz, 6H, 2 × CH3), 1.98–2.00 (m, 3H, =CH3), 2.56 (s, 3H, ArCH3), 3.57–3.61 (m, 1H, CH), 4.66–4.69 (d, 2H, OCH2), 5.95–6.06 (m, 2H, 2 × =CH), 6.90 (s, 1H, Ar), 6.98 (d, J = 7.5 Hz, 1H, Ar), 7.34 (d, J = 7.8 Hz, 1H, Ar). 13C-NMR (75 MHz, CDCl3): δ 18.1 (CH3), 21.5 (ArCH3), 23.0 (2 × CH3), 26.8 (CH), 68.9 (OCH2), 112.9 (Ar), 121.4 (Ar), 126.1 (=CH), 127.0 (Ar), 129.1 (=CH), 134.5 (Ar), 136.3 (Ar), 156.1 (Ar). Mixture of E/Z isomers with ratio of 5.2/1. For sake of clarity, we have reported only the signals related to the major isomer. Anal. Calcd for C14H20O: C, 82.30; H, 9.87. Found: C, 82.33; H, 9.84.
1-isopropyl-4-methyl-2-((3-methylbut-2-en-1-yl)oxy)benzene (11): pale yellow oil, 78% yield. 1H-NMR (300 MHz, CDCl3): δ 1.38 (d, J = 7.2 Hz, 6H, 2 × CH3), 1.90–1.96 (m, 6H, 2 × CH3), 2.49 (s, 3H, ArCH3), 3.45–3.54 (m, 1H, CH), 4.68 (d, 2H, J = 6.6 Hz, OCH2), 5.66–5.71 (m, 1H, =CH), 6.85 (s, 1H, Ar), 6.91 (d, J = 8.1 Hz, 1H, Ar), 7.26 (d, J = 7.5 Hz, 1H, Ar). 13C-NMR (75 MHz, CDCl3): δ 18.3 (CH3), 21.5 (ArCH3), 23.0 (2 × CH3), 25.9 (CH3), 26.6 (CH), 65.2 (OCH2), 112.8 (Ar), 120.7 (-CH=), 121.2 (Ar), 126.0 (Ar), 134.5 (Ar), 136.2 (Ar), 137.0 (=C), 156.1 (Ar). Anal. Calcd for C15H22O: C, 82.52; H, 10.16. Found: C, 82.56; H, 10.12.
1-isopropyl-4-methyl-2-(pentyloxy)benzene (12): colourless oil, 88% yield. 1H-NMR (300 MHz, CDCl3): δ 1.30 (t, J = 6.9 Hz, 3H, CH3), 1.58 (d, J = 6.9 Hz, 6H, 2 × CH3), 1.71–1.85 (m, 4H, CH2), 2.09–2.19 (m, 2H, CH2), 2.66 (s, 3H, ArCH3), 3.63–3.72 (m, 1H, CH), 4.23–4.28 (m, 2H, OCH2), 6.99 (s, 1H, Ar), 7.06 (d, J = 7.5 Hz, 1H, Ar), 7.43 (d, J = 7.5 Hz, 1H, Ar). 13C-NMR (75 MHz, CDCl3): δ 14.4 (CH3), 21.6 (ArCH3), 22.8 (CH2), 23.1 (2 × CH3), 27.0 (CH), 28.8 (CH2), 29.5 (CH2), 68.0 (OCH2), 112.3 (Ar), 121.2 (Ar), 126.0 (Ar), 134.3 (Ar), 136.4 (Ar), 156.5 (Ar). Anal. Calcd for C15H24O: C, 81.76; H, 10.98. Found: C, 81.80; H, 11.02.
ethyl 2-(2-isopropyl-5-methylphenoxy)acetate (13): pale yellow oil, 69% yield. 1H-NMR (300 MHz, CDCl3): δ 1.36–1.40 (m, 9H, 3 × CH3), 2.41 (s, 3H, ArCH3), 3.52–3.55 (m, 1H, CH), 4.30–4.38 (m, 2H, OCH2CH3), 4.70 (s, 2H, OCH2), 6.66 (s, 1H, Ar), 6.89 (d, J = 7.5 Hz, 1H, Ar), 7.23 (d, J = 7.5 Hz, 1H, Ar). 13C-NMR (75 MHz, CDCl3) δ 14.2 (CH3), 21.3 (ArCH3), 22.8 (2 × CH3), 26.8 (CH), 61.1 (OCH2CH3), 65.6 (OCH2), 112.3 (Ar), 122.3 (Ar), 126.3 (Ar), 134.5 (Ar), 136.2 (Ar), 155.2 (Ar), 169.1 (C=O). Anal. Calcd for C14H20O3: C, 71.16; H, 8.53. Found: C, 71.20; H, 8.49.
(E)-2-((3,7-dimethylocta-2,6-dien-1-yl)oxy)-1-isopropyl-4-methylbenzene (14): colourless oil, 82% yield. 1H-NMR (300 MHz, CDCl3): δ 1.33 (d, J = 6.3 Hz, 6H, 2 × CH3), 1.74 (s, 3H, CH3), 1.81 (s, 3H, CH3), 1.85 (s, 3H, CH3), 2.19–2.27 (m, 4H, 2 × CH2), 2.44 (s, 3H, ArCH3), 3.42–3.44 (m, 1H, CH), 4.65 (d, J = 7.5 Hz, 2H, OCH2), 5.20–5.23 (m, 1H, =CH), 5.61–5.64 (m, 1H, =CH), 6.8 (s, 1H, Ar), 6.85 (d, J = 7.5 Hz, 1H, Ar), 7.21 (d, J = 7.8 Hz, 1H, Ar). 13C-NMR (75 MHz, CDCl3): δ 16.7 (CH3), 17.8 (CH3), 21.5 (ArCH3), 22.9 (2 × CH3), 25.8 (CH3), 26.5 (CH2), 26.6 (CH), 39.6 (CH2), 65.1 (OCH2), 112.8 (Ar), 120.5 (=CH), 121.1 (Ar), 124.0 (=CH), 125.9 (Ar), 131.7 (=C), 134.4 (Ar), 136.2 (Ar), 140.1 (=C), 156.1 (Ar). Mixture of E/Z isomers with ratio of 9.3/1. For sake of clarity, we have reported only the signals related to the major isomer. Calcd for C20H30O: C, 83.86; H, 10.56. Found: C, 83.80; H, 10.51.
2-(benzyloxy)-1-isopropyl-4-methylbenzene (15): pale yellow oil, 88% yield. 1H-NMR (300 MHz, CDCl3): δ 1.30 (d, J = 7.2 Hz, 6H, 2× CH3), 2.40 (s, 3H, ArCH3), 3.41–3.51 (m, 1H, CH), 5.13 (s, 2H, OCH2), 6.83 (s, 1H, Ar), 6.85 (d, J = 8.1 Hz, 1H, Ar), 7.21 (d, J = 7.8 Hz, 1H, Ar), 7.37–7.55 (m, 5H, Ar). 13C-NMR (75 MHz, CDCl3): δ 21.4 (ArCH3), 22.9 (2 × CH3), 26.6 (CH), 70.0 (OCH2), 112.7 (Ar), 121.5 (Ar), 126.0 (Ar), 127.2 (2 × Ar), 127.7 (Ar), 128.6 (2 × Ar), 134.4 (Ar), 136.4 (Ar), 137.7 (Ar), 155.9 (Ar). Anal. Calcd for C17H20O: C, 84.96; H, 8.39. Found: C, 84.90; H, 8.33.
1-isopropyl-4-methyl-2-((2-methylbenzyl)oxy)benzene (16): pale yellow oil, 88% yield. 1H-NMR (300 MHz, CDCl3): δ 1.58 (d, J = 7.2 Hz, 6H, 2 × CH3), 2.70 (s, 6H, 2 × ArCH3), 3.72-3.83 (m, 1H, CH), 5.32 (s, 2H, OCH2), 7.13–7.15 (m, 2H, Ar), 7.48–7.58 (m, 4H, Ar), 7.81–7.83 (m, 1H, Ar). 13C-NMR (75 MHz, CDCl3): δ 19.2 (ArCH3), 21.8 (ArCH3), 23.3 (2 × CH3), 26.8 (CH), 68.7 (OCH2), 112.7 (Ar), 121.8 (Ar), 126.3 (Ar), 126.4 (Ar), 128.3 (Ar), 128.5 (Ar), 135.0 (Ar), 134.6 (Ar), 135.8 (Ar), 136.6 (Ar), 136.6 (Ar), 156.2 (Ar). Anal. Calcd for C18H22O: C, 84.99; H, 8.72. Found: C, 84.95; H, 8.77.
1-isopropyl-4-methyl-2-((4-methylbenzyl)oxy)benzene (17): pale yellow oil, 77% yield. 1H-NMR (300 MHz, CDCl3): δ 1.68 (d, J = 6.9 Hz, 6H, 2 × CH3), 2.75 (s, 6H, 2 × ArCH3), 3.82–3.87 (m, 1H, CH), 5.38 (s, 2H, OCH2), 7.16 (s, 1H, Ar), 7.19 (d, J = 8.1 Hz, 1H, Ar), 7.54–7.59 (m, 3H, Ar), 7.75 (d, J = 8.4 Hz, 1H, Ar). 13C-NMR (75 MHz, CDCl3): δ 21.6 (ArCH3), 21.8 (ArCH3), 23.3 (2 × CH3), 27.1 (CH), 70.2 (OCH2), 113.0 (Ar), 121.8 (Ar), 126.3 (Ar), 127.7 (2 × Ar), 129.6 (2 × Ar), 128.6 (Ar), 135.0 (Ar), 136.6 (Ar), 137.7 (Ar), 156.3 (Ar). Anal. Calcd for C18H22O: C, 84.99; H, 8.72. Found: C, 84.93; H, 8.70.
2-((3,5-dimethylbenzyl)oxy)-1-isopropyl-4-methylbenzene (18): colourless oil, 67% yield. 1H-NMR (400 MHz, CDCl3): δ 1.28 (d, J = 6.9 Hz, 6H, 2 × CH3), 2.38 (s, 3H, ArCH3), 2.40 (bs, 6H, 2 × ArCH3), 3.40–3.47 (m, 1H, CH), 5.04 (s, 2H, OCH2), 6.80 (s, 1H, Ar), 6.82 (d, J = 7.9 Hz, 1H, Ar), 7.02 (s, 1H, Ar), 7.12 (s, 2H, Ar), 7.18 (d, J = 7.6 Hz, 1H, Ar). 13C-NMR (101 MHz, CDCl3): δ 21.3 (2 × ArCH3), 21.4 (ArCH3), 22.9 (2 × CH3), 26.6 (CH), 70.2 (OCH2), 112.8 (Ar), 121.4 (Ar), 125.0 (2 × Ar), 125.9 (Ar), 129.4 (Ar), 134.4 (Ar), 136.4 (Ar), 137.6 (Ar), 138.1 (2 × Ar), 156.0 (Ar). Anal. Calcd for C19H24O3: C, 85.03; H, 9.01. Found: C, 85.08; H, 9.00.
1-isopropyl-2-((3-methoxybenzyl)oxy)-4-methylbenzene (19): colourless oil, 82% yield. 1H-NMR (400 MHz, CDCl3): δ 1.28 (d, J = 6.9 Hz, 6H, 2 × CH3), 2.37 (s, 3H, ArCH3), 3.38–3.48 (m, 1H, CH), 3.87 (s, 3H, OCH3), 5.09 (s, 2H, OCH2), 6.79 (s, 1H, Ar), 6.82 (d, J = 7.8 Hz, 1H, Ar), 6.90–6.92 (m, 1H, Ar), 7.07–7.08 (m, 2H, Ar), 7.17 (d, J = 7.7 Hz, 1H, Ar), 7.35 (t, J = 8.1 Hz, 1H, Ar). 13C-NMR (101 MHz, CDCl3): δ 21.4 (ArCH3), 22.8 (2 × CH3), 26.7 (CH), 55.5 (OCH3), 69.8 (OCH2), 112.5 (Ar), 112.7 (Ar), 113.2 (Ar), 119.3 (Ar), 121.5 (Ar), 126.0 (Ar), 129.6 (Ar), 134.4 (Ar), 136.4 (Ar), 139.3 (Ar), 155.8 (Ar). Anal. Calcd for C18H22O2: C, 79.96; H, 8.20. Found: C, 79.90; H, 8.25.
1-isopropyl-4-methyl-2-((2-(trifluoromethyl)benzyl)oxy)benzene (20): colourless oil, 77% yield. 1H-NMR (300 MHz, CDCl3): δ 1.39–1.42 (m, 6H, 2 × CH3), 2.46 (s, 3H, ArCH3), 3.55–3.57 (m, 1H, CH), 5.42 (s, 2H, OCH2), 6.85 (s, 1H, Ar), 6.94 (d, J = 7.5 Hz, 1H, Ar), 7.30 (d, J = 7.5 Hz, 1H, Ar), 7.51–7.54 (m, 1H, Ar), 7.68–7.71 (m, 1H, Ar), 7.82 (d, J = 7.5 Hz, 1H, Ar), 7.96 (d, J = 7.8 Hz, 1H, Ar). 13C-NMR (75 MHz, CDCl3): δ 21.4 (ArCH3), 22.9 (2 × CH3), 26.7 (CH), 66.3 (t, 4JC-F = 3.4 Hz, OCH2), 112.7 (Ar), 121.9 (Ar), 124.6 (d, 1JC-F = 272.3 Hz, CF3), 125.9 (q, 2JC-F = 57 Hz, Ar), 126.2 (Ar) 127.2 (d, 3JC-F = 30.9 Hz, Ar), 127.6 (Ar), 128.4 (Ar), 132.3 (Ar), 134.4 (Ar), 136.5 (Ar), 136.6 (Ar), 155.5 (Ar). 19F NMR (564.7 MHz, CDCl3) δ−58.69 (s, 3F, CF3). Anal. Calcd for C18H19F3O: C, 70.12; H, 6.21. Found: C, 70.08; H, 6.23.
1-isopropyl-4-methyl-2-((3-(trifluoromethyl)benzyl)oxy)benzene (21): colourless oil, 69% yield. 1H-NMR (300 MHz, CDCl3): δ 1.59–1.63 (m, 6H, 2 × CH3), 2.65–2.66 (m, 3H, ArCH3), 3.74–3.77 (m, 1H, CH), 5.35 (s, 2H, OCH2), 7.06 (s, 1H, Ar), 7.13 (d, J = 7.5 Hz, 1H, Ar), 7.48–7.51 (m, 1H, Ar), 7.75–7.78 (m, 1H, Ar), 7.87 (d, J = 8.4 Hz, 1H, Ar), 7.93 (d, J = 7.5 Hz, 1H, Ar), 8.08 (s, 1H, Ar). 13C-NMR (75 MHz, CDCl3): δ 21.5 (ArCH3), 23.0 (2 × CH3), 27.0 (CH), 69.3 (OCH2), 112.9 (Ar), 121.0 (d, 1JC-F = 274.6 Hz, CF3), 122.2 (Ar), 124.0 (m, Ar), 124.7 (q, 4JC-F = 3.4 Hz, Ar), 126.4 (Ar), 129.3 (Ar), 130.5 (Ar), 131.2 (d, 3JC-F = 32.0 Hz, Ar), 134.6 (Ar), 136.7 (Ar), 139.1 (Ar), 155.8 (Ar). 19F NMR (564.7 MHz, CDCl3) δ−60.98 (s, 3F, CF3). Anal. Calcd for C18H19F3O: C, 70.12; H, 6.21. Found: C, 70.10; H, 6.20.
1-isopropyl-4-methyl-2-((4-(trifluoromethyl)benzyl)oxy)benzene (22): colourless oil, 87% yield. 1H-NMR (300 MHz, CDCl3): δ 1.46 (d, J = 7.2 Hz, 6H, 2 × CH3), 2.51 (s, 3H, ArCH3), 3.52–3.61 (m, 1H, CH), 5.27 (s, 2H, OCH2), 6.900 (s, 1H, Ar), 6.99 (d, J = 8.4 Hz, 1H, Ar), 7.35 (d, J = 7.5 Hz, 1H, Ar), 7.73 (d, J = 7.5 Hz, 2H, Ar), 7.83 (d, J = 8.7 Hz, 1H, Ar). 13C-NMR (75 MHz, CDCl3): δ 21.4 (ArCH3), 22.9 (2 × CH3), 26.8 (CH), 69.1 (OCH2), 112.7 (Ar), 120.8 (d, 1JC-F = 273.4 Hz, CF3), 122.0 (Ar), 125.6 (q, 4JC-F = 3.4 Hz, Ar), 126.3 (Ar) 127.2 (2 × Ar), 129.8 (m, 2 × Ar), 134.4 (Ar), 136.6 (Ar), 141.9 (Ar), 155.6 (Ar). 19F NMR (564.7 MHz, CDCl3) δ−60.80 (s, 3F, CF3). Anal. Calcd for C18H19F3O: C, 70.12; H, 6.21. Found: C, 70.16; H, 6.22.
2-((3,5-bis(trifluoromethyl)benzyl)oxy)-1-isopropyl-4-methylbenzene (23): colourless oil, 80% yield. 1H-NMR (400 MHz, CDCl3): δ 1.27 (d, J = 6.9 Hz, 6H, 2 × CH3), 2.37 (s, 3H, ArCH3), 3.33–3.43 (m, 1H, CH), 5.20 (s, 2H, OCH2), 6.75 (s, 1H, Ar), 6.86 (d, J = 7.7 Hz, 1H, Ar), 7.19 (d, J = 7.7 Hz, 1H, Ar), 7.89 (s, 1H, Ar), 7.96 (s, 2H, Ar). 13C-NMR (101 MHz, CDCl3): δ 21.3 (ArCH3), 22.8 (2 × CH3), 26.7 (CH), 68.6 (OCH2), 112.7 (Ar), 119.2 (Ar), 121.6–121.8 (m, Ar), 122.3 (Ar), 123.3 (d, 1JC-F = 272.5 Hz, 2 × CF3), 126.3 (Ar), 126.9 (Ar), 127.0 (Ar), 127.4 (Ar), 131.9 (q, 2JC-F = 33.4 Hz, Ar), 134.4 (Ar), 136.6 (Ar), 140.3 (Ar), 155.1 (Ar). 19F NMR (564.7 MHz, CDCl3) δ−66.85 (s, 3F, CF3). Anal. Calcd for C19H18F6O: C, 60.64; H, 4.82. Found: C, 60.60; H, 4.77.
4-((2-isopropyl-5-methylphenoxy)methyl)benzonitrile (24): pale yellow solid, 71% yield, mp = 76–78 °C. 1H-NMR (300 MHz, CDCl3): δ 1.34–1.36 (m, 6H, 2 × CH3), 2.41 (s, 3H, ArCH3), 3.46–3.50 (m, 1H, CH), 5.19 (s, 2H, OCH2), 6.79 (s, 1H, Ar), 6.89 (d, J = 7.5 Hz, 1H, Ar), 7.24 (d, J = 7.5 Hz, 1H, Ar), 7.63 (d, J = 7.8 Hz, 2H, Ar), 7.72 (d, J = 8.1 Hz, 2H, Ar). 13C-NMR (75 MHz, CDCl3): δ 21.4 (ArCH3), 22.9 (2 × CH3), 26.7 (CH), 68.9 (OCH2), 111.5 (Ar), 112.6 (Ar), 118.9 (CN), 122.1 (Ar), 126.2 (Ar), 127.4 (2 × Ar), 132.4 (2 × Ar), 134.3 (Ar), 136.5 (Ar), 143.2 (Ar), 155.3 (Ar). Anal. Calcd for C18H19NO: C, 81.47; H, 7.22; N, 5.28. Found: C, 81.50; H, 7.20; N, 5.31.
2-((3-fluorobenzyl)oxy)-1-isopropyl-4-methylbenzene (25): colourless oil, 82% yield. 1H-NMR (300 MHz, CDCl3): δ 1.59–1.61 (d, J = 6.3 Hz, 6H, 2 × CH3), 2.65 (s, 3H, ArCH3), 3.71–3.81 (m, 1H, CH), 5.30 (s, 2H, OCH2), 7.03 (s, 1H, Ar), 7.12 (d, J = 8.4 Hz, 1H, Ar), 7.25–7.31 (m, 1H, Ar), 7.47–7.52 (m, 3H, Ar), 7.57–7.64 (m, 1H, Ar). 13C-NMR (75 MHz, CDCl3): δ 21.6 (ArCH3), 23.1 (2 × CH3), 27.0 (CH), 69.3 (OCH2), 112.8 (Ar), 114.2 (d, 2JC-F = 21.7 Hz, Ar), 114.8 (d, 2JC-F = 21.7 Hz, Ar), 122.1 (Ar), 122.7 (d, 4JC-F = 2.3 Hz, Ar), 126.4 (Ar), 130.3 (d, 3JC-F = 8.0 Hz, Ar), 134.6 (Ar), 136.6 (Ar), 140.6 (d, 3JC-F = 6.8 Hz, Ar), 155.9 (Ar), 163.3 (d, 1JC-F = 244.9 Hz, Ar-F). 19F NMR (564.7 MHz, CDCl3) δ−111.18 (ddd, 1F, JF–H = 7.91 Hz (ortho), 6.2 Hz (meta), CF). Anal. Calcd for C17H19FO: C, 79.04; H, 7.41. Found: C, 79.10; H, 7.50.
1,3-difluoro-2-((2-isopropyl-5-methylphenoxy)methyl)benzene (26): white solid, 83% yield, mp = 91–92 °C. 1H-NMR (300 MHz, CDCl3): δ 1.22 (d, J = 7.2 Hz, 6H, 2 × CH3), 2.42 (s, 3H, ArCH3), 3.26–3.35 (m, 1H, CH), 5.17 (s, 2H, OCH2), 6.86 (d, J = 7.5 Hz, 1H, Ar), 6.93–7.03 (m, 3H, Ar), 7.18 (d, J = 8.1 Hz, 1H, Ar), 7.31–7.41 (m, 2H, Ar). 13C-NMR (75 MHz, CDCl3): δ 21.4 (ArCH3), 22.8 (2 × CH3), 26.5 (CH), 58.2 (OCH2), 111.3 (2 × Ar), 111.6 (Ar), 113.0 (Ar), 121.9 (Ar), 126.1 (Ar), 130.5 (t, 3JC-F = 10.3 Hz, Ar), 134.7 (Ar), 136.4 (Ar), 155.7 (Ar), 162.0 (d, 1JC-F = 248.3 Hz, Ar-F), 162.1 (d, 1JC-F = 249.5 Hz, Ar-F). 19F NMR (564.7 MHz, CDCl3) δ−112.97 (t, 2F, JF–H = 7.5 Hz, CF). Anal. Calcd for C17H18F2O: C, 73.89; H, 6.57. Found: C, 73.93; H, 6.52.
2-((3,5-difluorobenzyl)oxy)-1-isopropyl-4-methylbenzene (27): white solid, 90% yield, mp = 35–36 °C. 1H-NMR (400 MHz, CDCl3): δ 1.27 (d, J = 6.9 Hz, 6H, 2 × CH3), 2.35 (s, 3H, ArCH3), 3.35–3.45 (m, 1H, CH), 5.08 (s, 2H, OCH2), 6.70 (s, 1H, Ar), 6.76–6.84 (m, 2H, Ar), 6.99–7.03 (m, 2H, Ar), 7.18 (d, J = 7.7 Hz, 1H, Ar). 13C-NMR (101 MHz, CDCl3): δ 21.3 (ArCH3), 22.8 (2 × CH3), 26.6 (CH), 68.7 (OCH2), 103.0 (t, 2JC-F = 25.3 Hz, Ar), 109.5 (d, 2JC-F = 25.7 Hz, 2 × Ar), 112.6 (Ar), 121.9 (Ar), 126.2 (Ar), 134.4 (Ar), 136.5 (Ar), 141.8 (t, 3JC-F = 9.1 Hz, Ar), 155.2 (Ar), 163.1 (d, 1JC-F = 248.5 Hz, C-F), 163.2 (d, 1JC-F = 248.6 Hz, C-F). 19F NMR (564.7 MHz, CDCl3) δ−113.39 (t, 2F, JF–H = 7.5 Hz, CF). Anal. Calcd for C17H18F2O: C, 73.89; H, 6.57. Found: C, 73.93; H, 6.61.
2-((3-chlorobenzyl)oxy)-1-isopropyl-4-methylbenzene (28): yellow sticky oil, 91% yield. 1H-NMR (400 MHz, CDCl3): δ 1.28 (d, J = 6.8 Hz, 6H, 2 × CH3), 2.37 (s, 3H, ArCH3), 3.40–3.44 (m, 1H, CH), 5.08 (s, 2H, OCH2), 6.76 (s, 1H, Ar), 6.84 (d, J = 7.6 Hz, 1H, Ar), 7.19 (d, J = 7.6 Hz, 1H, Ar), 7.35–7.38 (m, 3H, Ar), 7.49 (s, 1H, Ar). 13C-NMR (101 MHz, CDCl3): δ 21.4 (ArCH3), 22.9 (2 × CH3), 26.6 (CH), 69.2 (OCH2), 112.7 (Ar), 121.8 (Ar), 125.1 (Ar), 126.1 (Ar), 127.1 (Ar), 127.9 (Ar), 129.8 (Ar), 134.4 (Ar), 136.4 (Ar), 139.8 (Ar), 155.6 (Ar). Anal. Calcd for C17H19ClO: C, 74.31; H, 6.97. Found: C, 74.27; H, 6.90.
2-((4-chlorobenzyl)oxy)-1-isopropyl-4-methylbenzene (29): colourless oil, 74% yield. 1H-NMR (300 MHz, CDCl3): δ 1.43–1.46 (m, 6H, 2 × CH3), 2.52 (s, 3H, ArCH3), 3.55–3.58 (m, 1H, CH), 5.17 (s, 2H, OCH2), 6.90 (s, 1H, Ar), 6.98 (d, J = 7.5 Hz, 1H, Ar), 7.33 (d, J = 7.8 Hz, 1H, Ar), 7.50–7.53 (m, 4H, Ar). 13C-NMR (75 MHz, CDCl3) δ 21.6 (ArCH3), 23.0 (2 × CH3), 26.9 (CH), 69.3 (OCH2), 112.8 (Ar), 121.9 (Ar), 126.2 (Ar), 128.6 (2 × Ar), 128.9 (2 × Ar), 133.6 (Ar), 134.4 (Ar), 136.3 (Ar), 136.5 (Ar), 155.8 (Ar). Anal. Calcd for C17H19ClO: C, 74.31; H, 6.97. Found: C, 74.37; H, 7.01.
2-chloro-1-((2-isopropyl-5-methylphenoxy)methyl)-4-methoxybenzene (30): white solid, 71% yield, mp = 84–86 °C. 1H-NMR (400 MHz, CDCl3): δ 1.25 (d, J = 6.9 Hz, 6H, 2 × CH3), 2.36 (s, 3H, ArCH3), 3.34–3.44 (m, 1H, CH), 3.85 (s, 3H, OCH3), 5.11 (s, 2H, OCH2), 6.79 (s, 1H, Ar), 6.81 (d, J = 7.9 Hz, 1H, Ar), 6.89 (dd, J = 8.6 Hz, 2.5 Hz, 1H, Ar), 7.00 (d, J = 2.5 Hz, 1H, Ar), 7.16 (d, J = 7.6 Hz, 1H, Ar), 7.51 (d, J = 8.6 Hz, 1H, Ar). 13C-NMR (101 MHz, CDCl3): δ 21.4 (ArCH3), 22.8 (2 × CH3), 26.6 (CH), 55.6 (OCH3), 67.1 (OCH2), 112.7 (Ar), 112.9 (Ar), 114.9 (Ar), 121.6 (Ar), 126.0 (Ar), 127.3 (Ar), 129.8 (Ar), 133.5 (Ar), 134.4 (Ar), 136.4 (Ar), 155.5 (Ar), 159.7 (Ar). Anal. Calcd for C18H21ClO2: C, 70.93; H, 6.94. Found: C, 70.88; H, 6.96.
2-((2-bromobenzyl)oxy)-1-isopropyl-4-methylbenzene (31): white sticky solid, 71% yield. 1H-NMR (300 MHz, CDCl3): δ 1.47 (d, J = 7.2 Hz, 6H, 2 × CH3), 2.52 (s, 3H, ArCH3), 3.59–3.66 (m, 1H, CH), 5.29 (s, 2H, OCH2), 6.94 (s, 1H, Ar), 6.98 (d, J = 7.5 Hz, 1H, Ar), 7.30–7.35 (m, 2H, Ar), 7.49–7.54 (m, 1H, Ar), 7.73–7.76 (m, 1H, Ar), 7.80 (d, J = 6.9 Hz, 1H, Ar). 13C-NMR (75 MHz, CDCl3): δ 21.4 (ArCH3), 22.9 (2 × CH3), 26.6 (CH), 70.0 (OCH2), 112.7 (Ar), 121.5 (Ar), 126.0 (Ar), 127.2 (Ar), 127.7 (Ar), 128.6 (Ar), 134.4 (Ar), 136.4 (Ar), 137.7 (Ar), 155.9 (Ar). Anal. Calcd for C17H19BrO: C, 63.69; H, 6.00. Found: C, 63.71; H, 5.57.
2-((4-bromobenzyl)oxy)-1-isopropyl-4-methylbenzene (32): colourless oil, 71% yield. 1H-NMR (300 MHz, CDCl3): δ 1.52 (d, J = 6.9 Hz, 6H, 2 × CH3), 2.58 (s, 3H, ArCH3), 3.61–3.70 (m, 1H, CH), 5.20 (s, 2H, OCH2), 6.96 (s, 1H, Ar), 7.05 (d, J = 7.5 Hz, 1H, Ar), 7.40 (d, J = 7.5 Hz, 1H, Ar), 7.52–7.54 (d, 2H, Ar), 7.70–7.74 (m, 2H, Ar). 13C-NMR (75 MHz, CDCl3): δ 21.7 (ArCH3), 23.1 (2 × CH3), 27.0 (CH), 69.4 (OCH2), 112.8 (Ar), 121.8 (Ar), 122.0 (Ar), 126.3 (Ar), 129.0 (2 × Ar), 131.9 (2 × Ar), 134.5 (Ar), 136.5 (Ar), 136.9 (Ar), 155.8 (Ar). Anal. Calcd for C17H19BrO: C, 63.69; H, 6.00. Found: C, 63.65; H, 6.07.
2-((4-iodobenzyl)oxy)-1-isopropyl-4-methylbenzene (33): yellowish sticky oil, 83% yield. 1H-NMR (400 MHz, CDCl3): δ 1.26 (d, J = 6.9 Hz, 6H, 2 × CH3), 2.36 (s, 3H, ArCH3), 3.33–3.43 (m, 1H, CH), 5.04 (s, 2H, OCH2), 6.74 (s, 1H, Ar), 6.82 (d, J = 7.7 Hz, 1H, Ar), 7.17 (d, J = 7.7 Hz, 1H, Ar), 7.23 (d, J = 8.2 Hz, 2H, Ar), 7.76 (d, J = 8.3 Hz, 1H, Ar). 13C-NMR (101 MHz, CDCl3): δ 21.4 (ArCH3), 22.8 (2 × CH3), 26.6 (CH), 69.3 (OCH2), 93.1 (Ar), 112.6 (Ar), 121.7 (Ar), 126.1 (Ar), 129.0 (2 × Ar), 134.3 (Ar), 136.4 (Ar), 137.4 (Ar), 137.6 (2 × Ar), 155.6 (Ar). Anal. Calcd for C17H19IO: C, 55.75; H, 5.23. Found: C, 55.80; H, 5.30.
1-isopropyl-4-methyl-2-((2-nitrobenzyl)oxy)benzene (34): brown solid, 77% yield, mp = 77–79 °C. 1H-NMR (300 MHz, CDCl3): δ 1.26 (d, J = 7.2 Hz, 6H, 2× CH3), 2.32 (s, 3H, ArCH3), 3.38–3.43 (m, 1H, CH), 5.48 (s, 2H, OCH2), 6.73 (s, 1H, Ar), 6.81 (d, J =7.5 Hz, 1H, Ar), 7.16 (d, J =7.5, 1H, Ar), 7.50–7.53 (m, 1H, Ar), 7.69–7.75 (m, 1H, Ar), 7.96 (d, J = 7.8 Hz, 1H, Ar), 8.20 (dd, J = 8.1 Hz, J = 1.2 Hz, 1H, Ar). Anal. Calcd for C17H19NO3: C, 71.56; H, 6.71; N, 4.91. Found: C, 71.60; H, 6.75; N, 4.88.
1-isopropyl-4-methyl-2-((3-nitrobenzyl)oxy)benzene (35): amber-yellow oil, 81% yield. 1H-NMR (300 MHz, CDCl3): δ 1.48–1.52 (m, 6H, 2 × CH3), 2.53 (s, 3H, ArCH3), 3.62–3.67 (m, 1H, CH), 5.27 (s, 2H, OCH2), 6.95 (s, 1H, Ar), 7.00 (d, J = 7.8 Hz, 1H, Ar), 7.33–7.37 (m, 1H, Ar), 7.65–7.71 (m, 1H, Ar), 7.97 (d, J = 6.9 Hz, 1H, Ar), 8.26–8.29 (m, 1H, Ar), 8.51 (s, 1H, Ar). 13C-NMR (75 MHz, CDCl3): δ 21.5 (ArCH3), 23.0 (2 × CH3), 27.0 (CH), 68.6 (OCH2), 112.7 (Ar), 121.8 (Ar), 122.3 (Ar), 122.7 (Ar), 126.3 (Ar), 129.7 (Ar), 133.0 (Ar), 134.3 (Ar), 136.6 (Ar), 140.1 (Ar), 148.5 (Ar), 155.5 (Ar). Anal. Calcd for C17H19NO3: C, 71.56; H, 6.71; N, 4.91. Found: C, 71.55; H, 6.73; N, 4.91.
1-isopropyl-4-methyl-2-((4-nitrobenzyl)oxy)benzene (36): white solid, 81% yield, mp = 81–83 °C. 1H-NMR (300 MHz, CDCl3): δ 1.24–1.26 (m, 6H, 2 × CH3), 2.33 (s, 3H, ArCH3), 3.36–3.40 (m, 1H, CH), 5.18 (s, 2H, OCH2), 6.70 (s, 1H, Ar), 6.82 (d, J = 7.5 Hz, 1H, Ar), 7.16 (d, J = 7.8 Hz, 1H, Ar), 7.63 (d, J = 8.4 Hz, 2H, Ar), 8.26–8.28 (m, 2H, Ar). 13C-NMR (75 MHz, CDCl3): δ 21.4 (ArCH3), 22.8 (2 × CH3), 26.7 (CH), 68.7 (OCH2), 112.5 (Ar), 122.0 (Ar), 123.9 (2 × Ar), 126.2 (Ar), 127.3 (2 × Ar), 134.3 (Ar), 136.5 (Ar), 145.1 (Ar), 147.4 (Ar), 155.1 (Ar). Anal. Calcd for C17H19NO3: C, 71.56; H, 6.71; N, 4.91. Found: C, 71.51; H, 6.67; N, 4.96.
1-((2-isopropyl-5-methylphenoxy)methyl)naphthalene (37): pale yellow oil, 76% yield. 1H-NMR (400 MHz, CDCl3): δ 1.21 (d, J = 6.9 Hz, 6H, 2 × CH3), 2.41 (s, 3H, ArCH3), 3.31–3.42 (m, 1H, CH), 5.53 (m, 2H, CH2O), 6.86 (d, J = 7.7 Hz, 1H, Ar), 6.95 (s, 1H, Ar), 7.20 (d, J = 7.7 Hz, 1H, Ar), 7.51–7.58 (m, 3H, Ar), 7.68 (d, J = 6.9 Hz, 1H, Ar), 7.90 (d, J = 8.2 Hz, 1H, Ar), 7.93–7.96 (m, 1H, Ar), 8.09–8.11 (m, 1H, Ar). 13C-NMR (101 MHz, CDCl3): δ 21.5 (ArCH3), 23.0 (2 × CH3), 26.4 (CH), 68.6 (OCH2), 112.6 (Ar), 121.6 (Ar), 123.8 (Ar), 125.4 (Ar), 125.9 (Ar), 126.0 (Ar), 126.1 (Ar), 126.3 (Ar), 128.7 (Ar), 128.8 (Ar), 131.5 (Ar), 133.0 (Ar), 133.7 (Ar), 134.5 (Ar), 136.4 (Ar), 155.9 (Ar). Anal. Calcd for C21H22O: C, 86.85; H, 7.64. Found: C, 86.84; H, 7.70.
4-((2-isopropyl-5-methylphenoxy)methyl)-1,1′-biphenyl (38): white solid, 78% yield, mp = 91–92 °C. 1H-NMR (400 MHz, CDCl3): δ 1.29 (d, J = 6.9 Hz, 6H, 2 × CH3), 2.38 (s, 3H, ArCH3), 3.40–3.50 (m, 1H, CH), 5.16 (s, 2H, OCH2), 6.83–6.84 (m, 2H, Ar), 7.19 (d, J = 7.8 Hz, 1H, Ar), 7.38–7.42 (m, 1H, Ar), 7.47–7.52 (m, 2H, Ar), 7.57 (d, J = 8.3 Hz, 1H, Ar), 7.64–7.68 (m, 4H, Ar). 13C-NMR (101 MHz, CDCl3): δ 21.4 (ArCH3), 22.9 (2 × CH3), 26.6 (CH), 69.7 (OCH2), 112.7 (Ar), 121.5 (Ar), 127.1 (2 × Ar), 127.3 (2 × Ar), 127.4 (Ar), 127.6 (2 × Ar), 128.8 (2 × Ar), 134.4 (Ar), 136.4 (Ar), 137.4 (Ar), 136.7 (Ar), 140.7 (Ar), 140.9 (Ar), 155.8 (Ar). Anal. Calcd for C23H24O: C, 87.30; H, 7.64. Found: C, 87.35; H, 7.67.
2-((2-isopropyl-5-methylphenoxy)methyl)isoindoline-1,3-dione (39): white solid, 79% yield, mp = 121–122 °C. 1H-NMR (300 MHz, CDCl3): δ 1.18 (d, J = 7.2 Hz, 6H, 2 × CH3), 2.36 (s, 3H, ArCH3); 3.24–3.33 (m, 1H, CH3), 5.67 (s, 2H, OCH2), 6.84 (d, J = 7.8 Hz, 1H, Ar), 7.02 (s, 1H, Ar), 7.12 (d, J = 7.8 Hz, 1H, Ar), 7.73–7.78 (m, 2H, Ar), 7.88–7.92 (m, 2H, Ar). 13C-NMR (75 MHz, CDCl3): δ 21.3 (ArCH3), 23.0 (2 × CH3), 26.5 (CH), 65.7 (OCH2), 115.0 (Ar), 123.2 (2 × Ar), 123.8 (2 × Ar), 126.3 (Ar), 131.8 (Ar), 134.5 (2 × Ar), 135.4 (Ar), 136.5 (Ar), 153.4 (Ar), 167.2 (2 × C=O). Anal. Calcd for C19H19NO3: C, 73.77; H, 6.19; N, 4.53. Found: C, 73.71; H, 6.24; N, 4.50.

3.4. Anti-Helicobacter pylori Activity

The MIC determination was performed by modified broth microdilution assay as previously described [24]. For MBC evaluation, 10 μL of suspensions without visible growth were spotted on Skirrow agar plates surface and incubated for 72 h at 37 °C in microaerophilic conditions and 100% humidity conditions. The MBC was defined as the concentration that killed 99.9% of the initial inoculum.

3.5. Cell Lines and Treatments

The human adenocarcinoma gastric cell line (AGS) was derived from an untreated human adenocarcinoma of the stomach and retained the same cytological characteristics of the malignant cells obtained from Caucasian patients [25]. The AGS cells (ECACC 89090402) were purchased from CLS Cell Lines Services GmbH (Epplheim, Germany) and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 4.5 g/L glucose, 2 mM L-glutamine, and 10% Foetal Bovine Serum (FBS) (EuroClone S.p.A., Pero, Italy). Working solutions of thymol (1) and its derivatives (9, 15, 24–26, 30, 34–36, 38, 39) (600 mM) were freshly prepared in dimethyl sulfoxide (DMSO) and DMEM according to the experimental design by serial dilutions in complete culture medium. The final concentration of DMSO in experiments was 0.14%. No toxicity on AGS cells was observed (data not shown). 5-Fluorouracil and carvacrol (Sigma-Aldrich, Milan, Italy) were used as positive controls.

3.6. Cell Viability

Cell viability was evaluated by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)) assay (Promega, Madison, WI, USA). The concentration ranges of thymol and its derivatives for the treatment was extrapolated from concentration-response curves built in preliminary experiments. Briefly, AGS cells were seeded in 96-well plates (6 × 103 cells/well) and treated for 24 h at 37 °C in a humidified atmosphere with 5% CO2 with several concentrations (50–800 μM) of each compound (5 replica wells for each treatment condition). Cells were incubated with the MTS solution for at least 1 h and cell viability was tested colorimetrically by measuring the absorbance at 490 nm using GloMax-Multi Detection System (Promega, Madison, WI, USA). Cell viability was reported as the percentage as compared with the untreated cells recognized as 100%. The IC50 value was determined from the concentration-response curves by nonlinear regression analysis [15].

3.7. Statistical Analysis

A p value of 0.05 was assessed as statistically significant. IC50 values were obtained using the GraphPad Prism 7 software (GraphPad Software, San Diego, CA, USA).

4. Conclusions

We have explored a thymol-based molecular library with large structural diversity to discover new dual-action agents characterized by the ability to reduce the growth of several strains of H. pylori and to show toxicity for AGS cells. This approach allowed us to demonstrate, as also reported for carvacrol analogues, that the antibacterial activity of these phenolic terpenes is not limited to the presence of the free OH group in the natural parent compounds and that their antimicrobial potential could be enlarged by chemical modifications. Indeed, the proper functionalization could improve the anti-Helicobacter pylori activity especially against strains endowed with a different susceptibility pattern to antibiotics currently used in therapy. Moreover, some derivatives could display an antiproliferative effect useful to assess them as dual-acting agents for contrasting the development of gastric cancer. Further studies will address the potential of these compounds to treat biofilm-associated H. pylori infections in vitro and in vivo due to the disaggregating ability of their parent compound [22] and the putative mechanism of action, which could be alternative to those reported in literature for the parent compound [26]. Future studies will be devoted to the role of these compounds on the activity and role of carbonic anhydrase in H. pylori [27].

Supplementary Materials

The following are available online. Figure S1: NMR 19F spectrum at 564.7 MHz of 20 in CDCl3. Figure S2: NMR 19F spectrum at 564.7 MHz of 21 in CDCl3. Figure S3: NMR 19F spectrum at 564.7 MHz of 22 in CDCl3. Figure S4: NMR 19F spectrum at 564.7 MHz of 23 in CDCl3. Figure S5: NMR 19F spectrum at 564.7 MHz of 25 in CDCl3. Figure S6: NMR 19F spectrum at 564.7 MHz of 26 in CDCl3. Figure S7: NMR 19F spectrum at 564.7 MHz of 27 in CDCl3.

Author Contributions

Conceptualization, S.C., D.S., and R.G.; methodology, S.C., F.S., P.G., and M.S.; formal analysis, A.P.S., M.C.D.M., S.C., and G.M.; writing and original draft preparation, S.C., C.C., A.G., and R.G. All authors have read and agreed to the published version of the manuscript.

Funding

This work was financed by intramural grants by Ministero Italiano dell’Università e della Ricerca (MIUR) FAR2019 (ex 60%), held by Simone Carradori.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds are available from the authors on request.

References

  1. Kowalczyk, A.; Przychodna, M.; Sopata, S.; Bodalska, A.; Fecka, I. Thymol and thyme essential oil—new insights into selected therapeutic applications. Molecules 2020, 25, 4125. [Google Scholar] [CrossRef]
  2. Kachur, K.; Suntres, Z. The antibacterial properties of phenolic isomers, carvacrol and thymol. Crit. Rev. Food Sci. Nutr. 2020, 60, 3042–3053. [Google Scholar] [CrossRef] [PubMed]
  3. Marchese, A.; Orhan, I.E.; Daglia, M.; Barbieri, R.; Di Lorenzo, A.; Nabavi, S.F.; Gortzi, O.; Izadi, M.; Nabavi, S.M. Antibacterial and antifungal activities of thymol: A brief review of the literature. Food Chem. 2016, 210, 402–414. [Google Scholar] [CrossRef] [PubMed]
  4. Ivanovich Reshetnyak, V.; Igorevich Burmistrov, A.; Veniaminovich Maev, I. Helicobacter pylori: Commensal, symbiont or pathogen? World J. Gastroenterol. 2021, 21, 545–560. [Google Scholar] [CrossRef] [PubMed]
  5. Grande, R.; Sisto, F.; Puca, V.; Carradori, S.; Ronci, M.; Aceto, A.; Muraro, R.; Mincione, G.; Scotti, L. Antimicrobial and Antibiofilm Activities of New Synthesized Silver Ultra-NanoClusters (SUNCs) Against Helicobacter pylori. Front. Microbiol. 2020, 11, 1–14. [Google Scholar] [CrossRef] [PubMed]
  6. Krzyżek, P.; Grande, R.; Migdał, P.; Paluch, E.; Gościniak, G. Biofilm formation as a complex result of virulence and adaptive responses of Helicobacter pylori. Pathogens 2020, 9, 1062. [Google Scholar] [CrossRef]
  7. Guglielmi, P.; Pontecorvi, V.; Rotondi, G. Natural compounds and extracts as novel antimicrobial agents. Expert Opin. Ther. Pat. 2020, 30, 949–962. [Google Scholar] [CrossRef] [PubMed]
  8. Tabassum, H.; Ahmad, I.Z. Molecular Docking and Dynamics Simulation Analysis of Thymoquinone and Thymol Compounds from Nigella sativa L. that Inhibit Cag A and Vac A Oncoprotein of Helicobacter pylori: Probable Treatment of H. pylori Infections. Med. Chem. (Los. Angeles). 2020, 17, 146–157. [Google Scholar] [CrossRef]
  9. Bkhaitan, M.M.; Alarjah, M.; Mirza, A.Z.; Abdalla, A.N.; El-Said, H.M.; Faidah, H.S. Preparation and biological evaluation of metronidazole derivatives with monoterpenes and eugenol. Chem. Biol. Drug Des. 2018, 92, 1954–1962. [Google Scholar] [CrossRef]
  10. Piscione, M.; Mazzone, M.; Di Marcantonio, M.C.; Muraro, R.; Mincione, G. Eradication of Helicobacter pylori and Gastric Cancer: A Controversial Relationship. Front. Microbiol. 2021, 12, 630852. [Google Scholar] [CrossRef]
  11. Islam, M.T.; Khalipha, A.B.R.; Bagchi, R.; Mondal, M.; Smrity, S.Z.; Uddin, S.J.; Shilpi, J.A.; Rouf, R. Anticancer activity of thymol: A literature-based review and docking study with emphasis on its anticancer mechanisms. IUBMB Life 2019, 71, 9–19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Kang, S.H.; Kim, Y.S.; Kim, E.K.; Hwang, J.W.; Jeong, J.H.; Dong, X.; Lee, J.W.; Moon, S.H.; Jeon, B.T.; Park, P.J. Anticancer effect of thymol on AGS human gastric carcinoma cells. J. Microbiol. Biotechnol. 2015, 26, 28–37. [Google Scholar] [CrossRef] [PubMed]
  13. Günes-Bayir, A.; Kocyigit, A.; Güler, E.M.; Kiziltan, H.S. Effects of thymol, a natural phenolic compound, on human gastric adenocarcinoma cells in vitro. Altern. Ther. Health Med. 2019, 25, 12–21. [Google Scholar] [PubMed]
  14. Günes-Bayir, A.; Kocyigit, A.; Guler, E.M.; Dadak, A. In vitro hormetic effect investigation of thymol on human fibroblast and gastric adenocarcinoma cells. Molecules 2020, 25, 3270. [Google Scholar] [CrossRef]
  15. Sisto, F.; Carradori, S.; Guglielmi, P.; Traversi, C.B.; Spano, M.; Sobolev, A.P.; Secci, D.; Di Marcantonio, M.C.; Haloci, E.; Grande, R.; et al. Synthesis and biological evaluation of carvacrol-based derivatives as dual inhibitors of H. pylori strains and AGS cell proliferation. Pharmaceuticals 2020, 13, 405. [Google Scholar] [CrossRef] [PubMed]
  16. Bergonzelli, G.E.; Donnicola, D.; Porta, N.; Corthésy-Theulaz, I.E. Essential oils as components of a diet-based approach to management of Helicobacter infection. Antimicrob. Agents Chemother. 2003, 47, 3240–3246. [Google Scholar] [CrossRef] [Green Version]
  17. Eftekhar, F.; Nariman, F.; Yousefzadi, M.; Hadian, J.; Ebrahimi, S.N. Anti-Helicobacter pylori activity and essential oil composition of Thymus caramanicus from Iran. Nat. Prod. Commun. 2009, 4, 1139–1142. [Google Scholar] [CrossRef] [Green Version]
  18. Falsafi, T.; Moradi, P.; Mahboubi, M.; Rahimi, E.; Momtaz, H.; Hamedi, B. Chemical composition and anti-Helicobacter pylori effect of Satureja bachtiarica Bunge essential oil. Phytomedicine 2015, 22, 173–177. [Google Scholar] [CrossRef]
  19. Eftekhari, M.; Ardekani, M.R.S.; Amin, M.; Attar, F.; Akbarzadeh, T.; Safavi, M.; Karimpour-Razkenari, E.; Amini, M.; Isman, M.; Khanavi, M. Oliveria decumbens, a bioactive essential oil: Chemical composition and biological activities. Iran. J. Pharm. Res. 2019, 18, 412–421. [Google Scholar] [CrossRef] [PubMed]
  20. Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017, 7. [Google Scholar] [CrossRef] [Green Version]
  21. Daina, A.; Zoete, V. A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. ChemMedChem 2016, 1117–1121. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46, 3–26. [Google Scholar] [CrossRef]
  23. Palmeira, A.; Sousa, E.; Vasconcelos, M.H.; Pinto, M.M. Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds. Curr. Med. Chem. 2012, 19, 1946–2025. [Google Scholar] [CrossRef] [PubMed]
  24. Sisto, F.; Scaltrito, M.M.; Russello, G.; Bonomi, A.; Dubini, F. Antimicrobial susceptibility testing of Helicobacter pylori determined by microdilution method using a new medium. Curr. Microbiol. 2009, 58, 559–563. [Google Scholar] [CrossRef]
  25. Barranco, S.C.; Townsend, C.M.; Casartelli, C.; Macik, B.G.; Burger, N.L.; Boerwinkle, W.R.; Gourley, W.K. Establishment and Characterization of an in Vitro Model System for Human Adenocarcinoma of the Stomach. Cancer Res. 1983, 43, 1703–1709. [Google Scholar]
  26. Aljaafari, M.N.; AlAli, A.O.; Baqais, L.; Alqubaisy, M.; AlAli, M.; Molouki, A.; Ong-Abdullah, J.; Abushelaibi, A.; Lai, K.-S.; Lim, S.-H.E. An Overview of the Potential Therapeutic Applications of Essential Oils. Molecules 2021, 26, 628. [Google Scholar] [CrossRef]
  27. Ronci, M.; Del Prete, S.; Puca, V.; Carradori, S.; Carginale, V.; Muraro, R.; Mincione, G.; Aceto, A.; Sisto, F.; Supuran, C.T.; et al. Identification and characterization of the α-CA in the outer membrane vesicles produced by Helicobacter pylori. J. Enzyme Inhib. Med. Chem. 2019, 34, 189–195. [Google Scholar] [CrossRef] [Green Version]
Molecules 26 01829 g001 550
Figure 1. Synthesis of the reported thymol-based compounds 2–39. (a) Functionalization of the OH moiety of thymol (1); (b) ester hydrolysis to provide compound 8.
Figure 1. Synthesis of the reported thymol-based compounds 2–39. (a) Functionalization of the OH moiety of thymol (1); (b) ester hydrolysis to provide compound 8.
Molecules 26 01829 g001
Table
Table 1. MIC and MBC values for thymol (1, parent compound), its semi-synthetic derivatives (2–39), and carvacrol against eight strains of H. pylori. Antibiotic susceptibility according to EUCAST guidelines (Clinical Breakpoint Tables v. 11.0, valid from 1 January 2021) is reported for each H. pylori strain.
Table 1. MIC and MBC values for thymol (1, parent compound), its semi-synthetic derivatives (2–39), and carvacrol against eight strains of H. pylori. Antibiotic susceptibility according to EUCAST guidelines (Clinical Breakpoint Tables v. 11.0, valid from 1 January 2021) is reported for each H. pylori strain.
CompoundMIC/MBC (μg/mL)
19023110RNCTC 11637F1F40/499F4F34/497
1 (thymol)128/128128/128128/128128/12864/6464/6464/6464/64
2˃128/˃128128/˃128˃128/˃128˃128/˃128128/128128/128˃128/˃128˃128/˃128
364/6464/12864/64128/12832/3232/3264/128128/128
4128/128128/128128/12864/128128/12864/6464/6464/64
5˃128/˃128˃128/˃128˃128/˃128˃128/˃128128/128˃128/˃128˃128/˃128128/128
6128/128128/128128/128128/128128/128128/128128/12864/64
7128/128128/128128/128128/128128/12864/64128/128128/128
864/12864/128128/12864/64128/128128/128128/128128/128
964/64128/12832/32128/12816/1616/1664/128128/128
1064/12864/128128/128128/12864/12864/6464/12864/64
1164/6464/128128/12864/12864/6464/6464/6464/64
1232/3264/128128/128128/12816/6416/1664/12864/128
13128/12864/12864/128128/128128/12864/128128/12864/64
14128/128128/12864/12864/64128/12832/32128/12864/64
1532/3264/6432/6464/6416/1616/1632/6464/64
1664/12864/6464/12864/6432/3232/32128/12864/128
1732/3264/12864/6464/12816/328/1664/6432/64
1864/128128/128128/128128/12832/3232/3232/3264/128
1964/12864/128128/12864/6432/6432/3232/32128/128
20128/˃128˃128/˃128˃128/˃128˃128/˃12864/6464/64˃128/˃128128/128
21128/˃128˃128/˃128˃128/˃128˃128/˃12864/12864/128˃128/˃128128/128
22128/˃128˃128/˃128128/˃128128/˃12832/6432/64˃128/˃12864/64
23128/˃128128/˃128128/˃128˃128/˃128˃128/˃128˃128/˃128˃128/˃128˃128/˃128
2416/1616/1616/1616/1616/164/432/3232/32
2532/3232/6464/6464/6416/328/1632/3232/64
2664/6464/128˃128/˃12864/12816/648/1632/32128/128
2764/12832/3264/6432/3232/3216/1632/3264/128
2864/128128/128128/128128/12832/3216/1632/32128/128
2964/12832/6464/12864/6416/3216/32128/12832/32
30128/12864/128128/128128/1288/816/1632/3264/64
3164/64128/128128/128128/12816/6416/1632/6464/128
3216/3264/12864/12864/12816/1616/648/1632/32
33128/12864/128128/128128/12832/3232/3232/32128/128
3464/64128/12864/64128/1288/164/864/6464/64
3532/3232/3232/6432/3216/324/464/12816/32
3632/6432/3216/1632/3232/3232/3232/32128/128
37˃128/˃128128/˃128˃128/˃128˃128/˃128128/˃128˃128/˃128˃128/˃128128/˃128
3832/6432/6432/6432/328/84/48/1616/32
3916/1632/6432/6416/3216/3216/3232/6416/32
carvacrol64/6464/6464/6464/6464/6432/6464/6416/32
Antibiotic susceptibilityMTZ−
CLR−
AMX−		MTZ−
CLR−
AMX−		MTZ+
CLR−
AMX−		MTZ+
CLR−
AMX−		MTZ−
CLR+
AMX−		MTZ+
CLR+
AMX−		MTZ+
CLR+
AMX−		MTZ+
CLR+
AMX−
Antibiotic susceptibility: MTZ+ = metronidazole resistant (MIC > 8 μg/mL); MTZ- = metronidazole susceptible (MIC ≤ 8 μg/mL); CLR+ = clarithromycin resistant (MIC > 0.5 μg/mL); CLR- = clarithromycin susceptible (MIC ≤ 0.25 μg/mL); AMX+ = amoxicillin resistant (MIC > 0.125 μg/mL); AMX- = amoxicillin susceptible (MIC ≤ 0.125 μg/mL). Compounds selected for in vitro anti-proliferative activity assays against AGS cells are highlighted in grey.
Table
Table 2. IC50 values of the selected and reference compounds are expressed as mean ± standard deviation (SD) of three experiments with quintuplicate determinations.
Table 2. IC50 values of the selected and reference compounds are expressed as mean ± standard deviation (SD) of three experiments with quintuplicate determinations.
CompoundIC50 (μM) a
thymol (1)200 ± 6.5
9100 ± 5.8
1593.5 ± 7.6
24365 ± 8.5
25607 ± 9.5
26396 ± 8.5
30613 ± 9.9
34600 ± 9.0
35na
36574 ± 9.0
38194 ± 6.0
39na
Carvacrol b300 ± 6.4
5-FU82.3 ± 5.6
a Data are expressed as mean ± SD, n = 3; na: not active at the maximum concentration tested (800 μM). b from [15].
Table
Table 3. In silico evaluated physicochemical properties of the top-rated compounds 9, 15, and 38.
Table 3. In silico evaluated physicochemical properties of the top-rated compounds 9, 15, and 38.
Compound91538
Molecular weight (MW) b206.32240.34316.44
H-bond acceptors (HBA)111
H-bond donators (HBD)000
Consensus Log PO/W *4.224.525.78
Lipinski violations011
GI absorptionhighhighlow
P-gp substratenonono
PAINS alertsno alertno alertno alert
WLOGP a4.304.556.21
TPSA (Å2) a,b9.239.239.23
XLOGP3 b5.005.256.50
Log S
(ESOL) b		−4.24−4.87−6.12
Fraction Csp3 b0.570.290.22
N° of rotatable bonds b545
MLOGP3.874.365.48
boiled-egg graph Molecules 26 01829 i001 Molecules 26 01829 i002 Molecules 26 01829 i003
bioavailability radar Molecules 26 01829 i004 Molecules 26 01829 i005 Molecules 26 01829 i006
*Arithmetic mean of the values predicted by five in silico methods: XLOGP3, WLOGP, MLOGP, SILICOS-IT, iLOGP. Parameters range required to satisfy the Lipinski’s rule of five: MW < 500 g/mol, HBD < 5, HBA < 10, log P < 5. a Parameters used for the boiled-egg graph. b Parameters used for the bioavailability radar. Bioavailability radar parameters functional ranges: XLOGP3 between −0.7 and +5.0, MW between 150–500 g/mol, TPSA between 20–130 Å2, log S not higher than 6, saturation: fraction of carbons in the sp3 hybridization not less than 0.25, and flexibility: no more than 9 rotatable bonds. Boiled-egg graph: white region: high probability of passive absorption by the gastrointestinal tract; yellow region: high probability of brain penetration.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Sisto, F.; Carradori, S.; Guglielmi, P.; Spano, M.; Secci, D.; Granese, A.; Sobolev, A.P.; Grande, R.; Campestre, C.; Di Marcantonio, M.C.; et al. Synthesis and Evaluation of Thymol-Based Synthetic Derivatives as Dual-Action Inhibitors against Different Strains of H. pylori and AGS Cell Line. Molecules 2021, 26, 1829. https://doi.org/10.3390/molecules26071829

AMA Style

Sisto F, Carradori S, Guglielmi P, Spano M, Secci D, Granese A, Sobolev AP, Grande R, Campestre C, Di Marcantonio MC, et al. Synthesis and Evaluation of Thymol-Based Synthetic Derivatives as Dual-Action Inhibitors against Different Strains of H. pylori and AGS Cell Line. Molecules. 2021; 26(7):1829. https://doi.org/10.3390/molecules26071829

Chicago/Turabian Style

Sisto, Francesca, Simone Carradori, Paolo Guglielmi, Mattia Spano, Daniela Secci, Arianna Granese, Anatoly P. Sobolev, Rossella Grande, Cristina Campestre, Maria Carmela Di Marcantonio, and et al. 2021. "Synthesis and Evaluation of Thymol-Based Synthetic Derivatives as Dual-Action Inhibitors against Different Strains of H. pylori and AGS Cell Line" Molecules 26, no. 7: 1829. https://doi.org/10.3390/molecules26071829

APA Style

Sisto, F., Carradori, S., Guglielmi, P., Spano, M., Secci, D., Granese, A., Sobolev, A. P., Grande, R., Campestre, C., Di Marcantonio, M. C., & Mincione, G. (2021). Synthesis and Evaluation of Thymol-Based Synthetic Derivatives as Dual-Action Inhibitors against Different Strains of H. pylori and AGS Cell Line. Molecules, 26(7), 1829. https://doi.org/10.3390/molecules26071829

Article Metrics

Back to TopTop